Lentivirus
Lentivirus can carry larger genetic material packages of RNA, which is then converted to DNA. During this process, the vectors are integrated into the genome of the target cell. This makes lentivirus best suited for ex vivo treatment of dividing cells, such as T cells, and stem cells. The treated cells will begin to divide and generate new cells once they are returned to the body, and the genetic material is copied into all the newly produced cells.
The GMP compliance production of clinical grade lentivirus for CAR-T and other gene-editing cellular product requires knowledge of the complex methods to generate, purify, and characterize lentivirus vectors in a well-established, proven GMP quality system. As a leader of lentivirus vector production, TFBS Bioscience combines the leading lentivirus production technology with comprehensive GMP procedural controls that have been developed to ensure clinical product quality, safety, and consistency for CAR-T and gene therapy clinical trials.
Lentivirus Production
With well-knowledge of comprehensive methods to generate, purify, and characterize lentivirus vectors in a well-established, proven GMP quality system, TFBS provides GMP compliance or high-quality (clinical) grade lentivirus production for CAR-T other gene-editing cellular product. As a leader of lentivirus production, TFBS Bioscience integrates the leading lentivirus production technology with comprehensive GMP procedural monitors, which have been developed to secure GMP/ High-quality (clinical) product quality, safety, and consistency for gene-editing cellular product clinical trials.
QC Testing
Lentiviral vectors QC testing assay development
Attributes of virus | Characteristics | Methodology | Research grade | High-quality | cGMP grade |
Identity | Apperarance | Visual inspection | ○ | ● | ● |
pH | pH Meter | ○ | ● | ● | |
VSV-G protein | Western Blot | ● | |||
Genetic composition/ integrity | NGS/DNA sequencing | ○ | ● | ||
Purity | Residual host cell proteins | ELISA | ○ | ● | |
Residual bovine plasma proteins | ELISA | ○ | ● | ||
Residual host cell DNA | q-PCR | ○ | ● | ||
Residual DNA size | DNA gel electrophoresis | ○ | ● | ||
Empty:full particles ratio | TEM | ○ | ● | ||
Residual plasmid DNA |
q-PCR | ○ | ● | ||
Process derived impurities |
Depends | ○ | ● | ||
Quantity | Viral genomes titer | q-PCR | ● | ● | ● |
LV physical titer (p24) | ELISA | ○ | ● | ● | |
Transducing titer |
Cell-based q-PCR | ○ | ● | ● | |
Safety | Endotoxin | Kinetic Chromogent LAL assay | ○ | ● | ● |
Sterility |
21 CFR | ● | ● | ● | |
Mycoplasma |
21 CFR or NAT | ● | ● | ● | |
Replication-competent virus (RCV) | Cell-based q-PCR or PERT | ○ | ● | ||
Testing for adventitious viruses | In vitro or in vivo test | ○ | ● | ||
Potency | Potency |
Customized Bioassay Method: Cell-based or Virus-based assay | ○ | ● | ● |